KBKatarina Baluchova

Katarina Baluchova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katarina Baluchova has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Charles Cunningham

    Medical Research Council–University of Glasgow Centre for Virus Research, Glasgow G11 5JR, United Kingdom

    5 shared publications
  • Gavin W. G. Wilkinson

    Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom

    5 shared publications
  • Derrick J. Dargan

    Medical Research Council–University of Glasgow Centre for Virus Research, Glasgow G11 5JR, United Kingdom

    4 shared publications
  • Derek Gatherer

    Division of Biomedical & Life Sciences, Faculty of Health & Medicine, Lancaster University, Lancaster, UK

    3 shared publications
  • Patricia Price

    Curtin Medical Research Institute, Curtin University, Bentley 6102, Australia

    3 shared publications
  • Andrew J. Davison

    Section of Medical Microbiology, Tenovus Building, School of Medicine, Cardiff University, Cardiff, United Kingdom. 2MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow, United Kingdom

    2 shared publications

Latest Publications

  • Toward harmonization of clinical molecular diagnostic reports: findings of an international survey

    by Deborah A. Payne, Katarina Baluchova, Graciela Russomando, Parviz Ahmad-Nejad, Cyril Mamotte, Francois Rousseau, Ron H.N. van Schaik, Kristin Marriott, Masato Maekawa, K.C. Allen Chan, et al.

    Background: The International Organization for Standardization (ISO) 15189 standard provides recommendations for the postexamination reporting phase to enhance quality in clinical laboratories. The purpose of this study was to encourage a broad discussion on current reporting practices for molecular diagnostic tests by conducting a global survey of such practices.Methods: The International Federation of Clinical Chemistry and Laboratory Medicine’s Committee for Molecular Diagnostics (IFCC C-MD) surveyed laboratories on selected ISO 15189 recommendations and topics. The survey addressed the following aspects: (1) laboratory demographics, (2) report format, (3) result reporting/layout, (4) comments in report and (5) interpretation and clinical decision-making information. Additionally, participants indicated categories needing standardization.Results: Sixteen responses from laboratories located in Asia, Europe, the Middle East, North America and South America were received. Several categories yielded 100% agreement between laboratories, whereas other categories had less than or equal to 50% concordance. Participants scored “nomenclature” and “description of methodologies” as the two most frequently cited aspects needing standardization.Conclusions: The postexamination phase requires extensive and consistent communication between the laboratory, the healthcare provider and the end user. Surveyed laboratories were most likely to follow explicit ISO 15189 recommendations vs. recommendations when the term(s) “where appropriate or where applicable” was used. Interpretation and reporting of critical values varied among participants. Although the outcome of this study may not fully represent the practices of all molecular testing laboratories in countries around the world, the survey identified and specified several recommendations that are requirements for harmonized reporting in molecular diagnostics.


  • Open Access

    The long-term outcomes of radical prostatectomy for very high-risk prostate cancer pT3b-T4 N0-1 on definitive histopathology

    by Jan Kliment, Boris Elias, Katarina Baluchova

    The Central European Journal of Urology is an open access quarterly-issued journal, which provides a forum for the presentation of original clinical, experimental and other research studies...


  • Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach

    by Deborah A. Payne, Katarina Baluchova, Katell H. Peoc'H, Ron H.N. van Schaik, K.C. Allen Chan, Masato Maekawa, Cyril Mamotte, Graciela Russomando, François Rousseau, Parviz Ahmad-Nejad


  • Genotyping of EGFR Mutations from Bronchial Cytological Specimens in Slovakian Lung Cancer Patients

    by K. Baluchova, M. Zahradnikova, P. Bakes, S. Trubacova, H. Novosadova, E. Halasova, I. Majer, P. Hlavcak

    Non-small cell lung cancer (NSCLC) is a histologically and molecularly heterogeneous disease predominating in Slovakia among newly diagnosed oncological disorders and leading in the number of associated deaths. NSCLC diagnostics has advanced especially in molecular typing of epidermal growth factor receptor (EGFR) and subsequent targeted molecular therapy using tyrosine-kinase inhibitor(s) (TKI). The selection of patients for targeted therapy, we describe in this study, is mostly guided through bronchial smears rather than more invasive biopsies. We identified 32 adenocarcinomas, 40 squamous-cell carcinomas, 12 large-cell carcinomas, along with two unspecified carcinomas, in the NSCLC group who had bronchial smears taken. The assessment of tumor cell number, and genomic DNA allowed for screening of clinically relevant somatic EGFR mutations in 86 patients. Using quantitative PCR, 12 patients (14 %) were recommended for EGFR-TKI therapy. The most prevalent EGFR HIT-a in the somatosome, terms introduced and defined in this study, were exon 19 deletions, which were found in combination with the TKI-resistant p.T790M mutation in exon 20 in one patient. The study describes a method that is minimally invasive, reliable, and meets all criteria of routine molecular diagnostics. A multidisciplinary approach of EGFR genotyping from bronchial smears implemented in the study allows expanding targeted molecular therapy in NSCLC patients.

  • High-resolution human cytomegalovirus transcriptome

    by Derek Gatherer, Sepehr Seirafian, Charles Cunningham, Mary Holton, Derrick J. Dargan, Katarina Baluchova, Ralph D. Hector, Julie Galbraith, Pawel Herzyk, Gavin W. G. Wilkinson, et al.

    Deep sequencing was used to bring high resolution to the human cytomegalovirus (HCMV) transcriptome at the stage when infectious virion production is under way, and major findings were confirmed by extensive experimentation using conventional techniques. The majority (65.1%) of polyadenylated viral RNA transcription is committed to producing four noncoding transcripts (RNA2.7, RNA1.2, RNA4.9, and RNA5.0) that do not substantially overlap designated protein-coding regions. Additional noncoding RNAs that are transcribed antisense to protein-coding regions map throughout the genome and account for 8.7% of transcription from these regions. RNA splicing is more common than recognized previously, which was evidenced by the identification of 229 potential donor and 132 acceptor sites, and it affects 58 protein-coding genes. The great majority (94) of 96 splice junctions most abundantly represented in the deep-sequencing data was confirmed by RT-PCR or RACE or supported by involvement in alternative splicing. Alternative splicing is frequent and particularly evident in four genes ( RL8A , UL74A , UL124 , and UL150A ) that are transcribed by splicing from any one of many upstream exons. The analysis also resulted in the annotation of four previously unrecognized protein-coding regions ( RL8A , RL9A , UL150A , and US33A ), and expression of the UL150A protein was shown in the context of HCMV infection. The overall conclusion, that HCMV transcription is complex and multifaceted, has implications for the potential sophistication of virus functionality during infection. The study also illustrates the key contribution that deep sequencing can make to the genomics of nuclear DNA viruses.


  • Open Access

    Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication

    by Richard J. Stanton, Katarina Baluchova, Derrick J. Dargan, Charles Cunningham, Orla Sheehy, Sepehr Seirafian, Brian P. McSharry, M. Lynne Neale, James A. Davies, Peter Tomasec, et al.

    Human cytomegalovirus (HCMV) in clinical material cannot replicate efficiently in vitro until it has adapted by mutation. Consequently, wild-type HCMV differ fundamentally from the passaged strains used for research. To generate a genetically intact source of HCMV, we cloned strain Merlin into a self-excising BAC. The Merlin BAC clone had mutations in the RL13 gene and UL128 locus that were acquired during limited replication in vitro prior to cloning. The complete wild-type HCMV gene complement was reconstructed by reference to the original clinical sample. Characterization of viruses generated from repaired BACs revealed that RL13 efficiently repressed HCMV replication in multiple cell types; moreover, RL13 mutants rapidly and reproducibly emerged in transfectants. Virus also acquired mutations in genes UL128, UL130, or UL131A, which inhibited virus growth specifically in fibroblast cells in wild-type form. We further report that RL13 encodes a highly glycosylated virion envelope protein and thus has the potential to modulate tropism. To overcome rapid emergence of mutations in genetically intact HCMV, we developed a system in which RL13 and UL131A were conditionally repressed during virus propagation. This technological advance now permits studies to be undertaken with a clonal, characterized HCMV strain containing the complete wild-type gene complement and promises to enhance the clinical relevance of fundamental research on HCMV.


  • Open Access

    Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture

    by Derrick J. Dargan, Elaine Douglas, Charles Cunningham, Fiona Jamieson, Richard J. Stanton, Katarina Baluchova, Brian P. McSharry, Peter Tomasec, Vincent C. Emery, Elena Percivalle, et al.

    Mutations that occurred during adaptation of human cytomegalovirus to cell culture were monitored by isolating four strains from clinical samples, passaging them in various cell types and sequencing ten complete virus genomes from the final passages. Mutational dynamics were assessed by targeted sequencing of intermediate passages and the original clinical samples. Gene RL13 and the UL128 locus (UL128L, consisting of genes UL128, UL130 and UL131A) mutated in all strains. Mutations in RL13 occurred in fibroblast, epithelial and endothelial cells, whereas those in UL128L were limited to fibroblasts and detected later than those in RL13. In addition, a region containing genes UL145, UL144, UL142, UL141 and UL140 mutated in three strains. All strains exhibited numerous mutations in other regions of the genome, with a preponderance in parts of the inverted repeats. An investigation was carried out on the kinetic growth yields of viruses derived from selected passages that were predominantly non-mutated in RL13 and UL128L (RL13+UL128L+), or that were largely mutated in RL13 (RL13−UL128L+) or both RL13 and UL128L (RL13−UL128L−). RL13−UL128L− viruses produced greater yields of infectious progeny than RL13−UL128L+ viruses, and RL13−UL128L+ viruses produced greater yields than RL13+UL128L+ viruses. These results suggest strongly that RL13 and UL128L exert at least partially independent suppressive effects on growth in fibroblasts. As all isolates proved genetically unstable in all cell types tested, caution is advised in choosing and monitoring strains for experimental studies of vulnerable functions, particularly those involved in cell tropism, immune evasion or growth temperance.


  • Open Access

    Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens

    by Charles Cunningham, Derek Gatherer, Birgitta Hilfrich, Katarina Baluchova, Derrick J. Dargan, Marian Thomson, Paul D. Griffiths, Gavin W. G. Wilkinson, Thomas F. Schulz, Andrew J. Davison

    We have assessed two approaches to sequencing complete human cytomegalovirus (HCMV) genomes (236 kbp) in DNA extracted from infected cell cultures (strains 3157, HAN13, HAN20 and HAN38) or clinical specimens (strains JP and 3301). The first approach involved amplifying genomes from the DNA samples as overlapping PCR products, sequencing these by the Sanger method, acquiring reads from a capillary instrument and assembling these using the Staden programs. The second approach involved generating sequence data from the DNA samples by using an Illumina Genome Analyzer (IGA), processing the filtered reads by reference-independent (de novo) assembly, utilizing the resulting sequence to direct reference-dependent assembly of the same data and finishing by limited PCR sequencing. Both approaches were successful. In particular, the investigation demonstrated the utility of IGA data for efficiently sequencing genomes from clinical samples containing as little as 3 % HCMV DNA. Analysis of the genome sequences obtained showed that each of the strains grown in cell culture was a mutant. Certain of the mutations were shared among strains from independent clinical sources, thus suggesting that they may have arisen in a common ancestor during natural infection. Moreover, one of the strains (JP) sequenced directly from a clinical specimen was mutated in two genes, one of which encodes a proposed immune-evasion function, viral interleukin-10. These observations imply that HCMV mutants exist in human infections.


  • Open Access

    High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169

    by Amanda J. Bradley, Nell S. Lurain, Peter Ghazal, Urmi Trivedi, Charles Cunningham, Katarina Baluchova, Derek Gatherer, Gavin W. G. Wilkinson, Derrick J. Dargan, Andrew J. Davison

    The genomes of commonly used variants of human cytomegalovirus (HCMV) strains Towne and AD169 each contain a substantial mutation in which a region (UL/b′) at the right end of the long unique region has been replaced by an inverted duplication of a region from the left end of the genome. Using high-throughput technology, we have sequenced HCMV strain Towne (ATCC VR-977) and confirmed the presence of two variants, one exhibiting the replacement in UL/b′ and the other intact in this region. Both variants are mutated in genes RL13, UL1, UL40, UL130, US1 and US9. We have also sequenced a novel AD169 variant (varUC) that is intact in UL/b′ except for a small deletion that affects genes UL144, UL142, UL141 and UL140. Like other AD169 variants, varUC is mutated in genes RL5A, RL13, UL36 and UL131A. A subpopulation of varUC contains an additional deletion affecting genes IRS1, US1 and US2.


  • Preliminary characterization of murine cytomegaloviruses with insertional and deletional mutations in the M34 open reading frame

    by Katarina Baluchova, Melissa Kirby, Mohammad M. Ahasan, Clive Sweet

    A viable virus could not be recovered from a mutant murine cytomegalovirus (MCMV) BAC in which the M34 ORF had been deleted (BACΔM34). In contrast, an M34 mutant virus (RcM34), in which the M34 ORF was interrupted by transposon insertion at nt 44,827 of the Smith MCMV BAC, was attenuated in replication both in tissue culture and in SCID mice. Similarly, mutant virus Rc3′ΔM34, in which the 3′‐end was deleted from nt 44,724 to nt 45,647, produced similar replication kinetics in tissue culture to RcM34 while BAC5′ΔM34, in which the 5′‐end from nt 43,083 up to nt 44,896 was deleted, was non‐viable like BACΔM34. A transcript analysis of wt and RcM34 virus‐infected cells showed that a truncated transcript encoding a putative protein of 624 amino acids was produced by RcM34, of which the amino terminal 582 amino acids would be identical to the predicted wt 854 amino acids product. Recent, re‐annotations of the MCMV genome have identified three putative M34 overlapping ORFs (m33.1, m34.1, and m34.2) that may be interrupted in the above mutants. All three were transcribed in RcM34 virus‐infected cells confirming that the RcM34 virus phenotype was probably due to interruption of the M34 ORF. These results suggest that M34, like human CMV UL34, is an essential gene. J. Med. Virol. 80: 1233–1242, 2008.